Phase 2 Breast Cancer Trial, Not Yet Recruiting
voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice
Who may and may not be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who may be able to join
- The person must be female.
- They must have been recently diagnosed with a type of breast cancer called Ductal Carcinoma in Situ (DCIS) and/or invasive breast cancer, confirmed by a tissue sample analysis.
- They must be between 40 and 85 years old at the time of diagnosis.
- They must have already had a lumpectomy (surgery to remove the tumour) where the tissue around the removed tumour was found to be clear of cancer cells.
- The tumour must be classified as a certain early stage (called Tis, T1, or T2).
- If the tumour is T2 stage, it must be no larger than 3 cm at its widest point.
- If the breast cancer tests positive for a protein called HER2, the treating doctor must be planning to give, or must have already given, a treatment that targets HER2.
- For people with invasive breast cancer, a procedure to check the lymph nodes under the arm must have been carried out, and those lymph nodes must have tested negative for cancer — with some exceptions noted below (confirm with trial site).
- People aged 70 or older with certain hormone-receptor-positive, HER2-negative, low-to-moderate grade tumours of 2 cm or smaller may not be required to have the lymph node check (confirm with trial site).
- For people aged 50–69 with certain low-to-moderate grade, hormone-receptor-positive, HER2-negative tumours of 2 cm or smaller and no signs of cancer in the armpit on imaging, the decision about whether the lymph node procedure is needed may be left to the surgeon (confirm with trial site).
- The person must agree to follow recommendations regarding a type of hormone-blocking medication called an aromatase inhibitor.
- Treatment with a specific internal radiation technique (brachytherapy) must be able to begin within 12 weeks of the lumpectomy, any follow-up margin surgery, or the end of chemotherapy.
- The person must be able to understand and be willing to sign a written consent form.
Who may not be able to join
Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.
- People who are pregnant or breastfeeding.
- People with an active disease affecting the body's connective tissues (called collagen-vascular disease).
- People with a condition called Paget's disease of the breast.
- People who have previously been diagnosed with DCIS or invasive breast cancer at any time before the current diagnosis.
- People who have previously had radiation therapy to the breast or chest area for any reason.
- People whose cancer is found in more than one separate area of the breast (called multicentric carcinoma).
- People who have breast cancer in both breasts at the same time.
- People whose surgical margins could not be properly assessed under a microscope, or where cancer cells were found at the edges of the removed tissue.
- People who received chemotherapy before surgery (called neoadjuvant chemotherapy).
- People where the surgical cavity left after the lumpectomy cannot be clearly identified or is not suitable for the radiation implant procedure, as determined by the treating doctor.
- People who have a medical, psychological, or social condition that, in the opinion of the treating doctor, could increase risk or make it difficult to follow the study requirements.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Bridget Quinn, MD, Virginia Commonwealth University
Phone: 804-628-6430
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Assess and compare the toxicity of a 1-day course of accelerated partial breast irradiation (APBI) to that of clinical trials: NSABP-B-39 (NCT00103181), RTOG-0413, TRIUMPH-T (NCT02526498), and ASHBY (NCT06185205)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 20 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.